Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of venetoclax-based therapy vs intensive chemotherapy in older adults with newly diagnosed Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ENElham NasrollahiSPS Papp

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis shows reduced infections in older adults with AML using venetoclax, suggesting trade-offs in therapy efficacy.

Key Points

  • Venetoclax therapy led to a lower incidence of infections within 60 days at 36.5%, compared to 48.6% for intensive chemotherapy.
  • Survival analysis indicated a median overall survival of 482 days with intensive chemotherapy versus 246 days for venetoclax.
  • Retrospective cohort study utilized propensity score matching to analyze outcomes pertaining to infection and cytopenic events in older adults.
  • Findings highlight the importance of balancing treatment efficacy and tolerability in managing older adults with AML.

Cite This Study

Nasrollahi et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3dbhttps://doi.org/10.1182/blood-2025-6996
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world analysis of treatment patterns and outcomes in older patients with Acute Myeloid Leukemia (AML) in the US community oncology setting2025
  2. 2Real-world survival outcomes with first-line venetoclax therapy in AML2025
  3. 3Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience2026
  4. 4Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation2025 · 4 citations
  5. 5Assessment of racial and age disparities in response and survival among acute myeloid leukemia (AML) patients treated with hypomethylating agents (HMA) and venetoclax.2026